UNION therapeutics to participate at Kempen Life Science Conference

HELLERUP, Denmark, April 21, 2023 /PRNewswire/ -- UNION therapeutics A/S (UNION), a privately-held, multi-asset, clinical stage, pharmaceutical development company focused on immunology and infectious disease, today announced participation at the Kempen Life Science Conference on April 25-26, 2023, in Amsterdam.

Contacts

Morten Boesen,
Chief Financial Officer,
UNION therapeutics A/S
+45 2381 5487
morten.boesen@uniontherapeutics.com

Sarah Toft-Jørgensen,
Director of Communications and IR,
UNION therapeutics A/S
+45 5385 3044
stj@uniontherapeutics.com

 About UNION therapeutics

UNION therapeutics is a privately held, mid- to late-stage, pharmaceutical development company advancing novel treatment options within immunology and infectious diseases, two large and fast-growing therapeutic areas. UNION is headquartered in Hellerup, Denmark, and led by an international team combining biotech entrepreneurs and seasoned pharma executives, with a track record of developing and launching more than fifteen marketed drugs.
Read more at www.uniontherapeutics.com 

The following files are available for download: